[Skip to content]

Royal Brompton & Harefield NHS Foundation Trust
Our research
Search our Site
Lung infection and immunity

Lung infection and immunity

    

Trust researchers with an active programme in lung infection and immunity (who work closely with colleagues in paediatrics) are:

 

Professor Eric Alton: developing and evaluating gene therapy in the treatment of cystic fibrosis. Professor Alton co-ordinates the UK CF Gene Therapy Consortium.

 

Dr Diana Bilton: diagnosis and assessment of infection in chronic suppurative lung disease particularly cystic fibrosis and bronchiectasis; developing and evaluating new therapies for airway infection and inflammation; chair of UK Cystic Fibrosis registry.

 

Dr Rosemary Boyton: genetics and immune mechanisms in chronic lung infection in cystic fibrosis and bronchiectasis; cellular responses in chronic allergic and infectious inflammatory lung disease with a view to elucidating pathological mechanisms and the development of effective and specific therapies including vaccines.

 

Dr Michael Loebinger: investigating the susceptibility, progression and prognosis of chronic infective lung diseases with reference to both the host and microbe. New biomarker and clinical endpoint development.  Bronchiectasis, cystic fibrosis, non tuberculous mycobacteria, tuberculosis, stem cells and immunology.

 

Dr Toby Maher: basic and translational research into idiopathic pulmonary fibrosis; the use of acoustic lung imaging in diagnosis and disease monitoring in patients with chronic respiratory conditions; biomarker discovery and development of new treatments for interstitial lung disease.

 

Dr Elizabeth Renzoni: diffuse/interstitial lung disease biology; its aetiology and the role of inflammatory mediators.

 

Professor Athol Wells: the biology and epidemiology of diffuse/interstitial lung disease biology and associated pulmonary hypertension; the definition of diffuse lung disease type and severity in genetic and laboratory studies; prognostic evaluation in interstitial lung disease and the development and evaluation of new therapies.

 

Dr Rob Wilson: pathogenesis of bronchiectasis; primary ciliary dyskinesia; non-invasive measures of lung inflammation; treatment of neutrophilic airway inflammation; non tuberculous mycobacteria; antibiotic trials in bronchiectasis and COPD.

 


More information about our research in lung infection and immunity is available from our list of active research studies in chronic suppurative lung disease and interstitial lung disease and our publications web pages.



 

Royal Brompton

Sydney Street,
London SW3 6NP
Tel: +44 (0)20 7352 8121

Harefield